MannKind Corp
Private Company
Funding information not available
Overview
MannKind Corporation has evolved from a development-stage enterprise into a multi-product biopharmaceutical company with a core mission of transforming chronic disease management through innovative, patient-centric inhaled solutions. Its competitive moat is anchored in the proprietary Technosphere® drug delivery platform, which has enabled the commercialization of Afrezza® and underpins a diversified portfolio and partnership strategy. The company is now demonstrating strong commercial execution, with FY2025 revenues reaching $349 million, driven by growth in its core products and strategic acquisitions like scPharmaceuticals.
Technology Platform
The Technosphere® platform is a proprietary dry powder formulation and inhalation system designed for the rapid pulmonary delivery of therapeutics, enabling non-invasive systemic administration of peptides and small molecules.
Pipeline
60| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Afrezza plus One Drop | Premium | Diabetes Mellitus, Type 2 | Approved | |
| Technosphere insulin | Diabetes Mellitus, Type 1 | Approved | |
| Afrezza + insulin degludec + Rapid-acting Insulin Analog + B... | Diabetes Mellitus, Type 1 | Approved | |
| Afrezza (insulin human) Inhalation Powder + insulin degludec | Type 1 Diabetes | Approved | |
| Technosphere® Insulin with MedTone C Inhaler + Technosphere ... | Type 1 Diabetes Mellitus | Phase 3 |
Opportunities
Risk Factors
Competitive Landscape
MannKind competes with injectable insulins and GLP-1s in diabetes, nebulized therapies in PAH, and standard diuretics in heart failure. Its primary differentiation is its non-invasive, convenient delivery platforms (inhalation, patch, on-body infusor), carving out unique niches in crowded therapeutic areas.
